Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer
Tomoko FunazoKyohei MoritaNaoya IkegamiChisato KonishiSatoshi NakaoRyo AriyasuMasato TakiKazuhiko NakagawaMoon Hee HwangChie YoshimuraToshiaki WakayamaYasuo Nishizaka
Author information

2017 Volume 56 Issue 17 Pages 2317-2320


Choroidal metastasis is rare in cancer patients and it may cause visual disturbances that reduce their quality of life. In non-small cell lung cancer (NSCLC), targeted therapy against actionable driver mutations has gradually replaced radiotherapy as the treatment of choice for choroidal metastasis. Recently, there have been several case reports of choroidal metastasis in patients with anaplastic lymphoma kinase (ALK)-rearranged NSCLC. We herein report the case of a 40-year-old Japanese woman diagnosed with choroidal metastasis of an ALK-rearranged NSCLC who received alectinib as the first-line chemotherapy. Alectinib may be the best treatment for choroidal metastasis in patients harboring an ALK translocation because of its favorable side effect profile involving visual disturbances.

Information related to the author
© 2017 by The Japanese Society of Internal Medicine
Previous article Next article